ASH 2022 | Correlation between ctDNA levels and outcomes in patients with NHL treated with CAR-T therapy
Paolo Caimi, MD, Cleveland Clinic, Cleveland, OH, discusses a Phase I trial (NCT03434769) that used circulating tumor DNA (ctDNA) analysis to assess the disease burden of patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) treated with CAR-T therapy. Lower ctDNA prior to CAR-T infusion was associated with better outcomes, and an undetectable ctDNA level after infusion was associated with improved progression-free survival (PFS) and overall survival (OS) outcomes. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bristol Myers Squibb: Membership on an entity’s Board of Directors or advisory committees; Genmab: Membership on an entity’s Board of Directors or advisory committees; Genentech: Membership on an entity’s Board of Directors or advisory committees; Takeda: Membership on an entity’s Board of Directors or advisory committees; MEI Pharma: Membership on an entity’s Board of Directors or advisory committees; ADC Therapeutics: Membership on an entity’s Board of Directors or advisory committees; Novartis: Membership on an entity’s Board of Directors or advisory committees; Kite Pharma: Membership on an entity’s Board of Directors or advisory committees.
